Kamil Kuca Selected Research

Atropine

7/2020	Safety and Efficacy of New Oximes to Reverse Low Dose Diethyl-Paraoxon-Induced Ventilatory Effects in Rats.
9/2018	Novel Group of AChE Reactivators-Synthesis, In Vitro Reactivation and Molecular Docking Study.
1/2018	The benefit of combinations of oximes for the ability of antidotal treatment to counteract sarin-induced brain damage in rats.
5/2017	Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs.
1/2011	Mono-oxime bisquaternary acetylcholinesterase reactivators with prop-1,3-diyl linkage-Preparation, in vitro screening and molecular docking.
11/2010	A comparison of neuroprotective efficacy of the oxime K203 and its fluorinated analogue (KR-22836) with obidoxime in Tabun-poisoned rats.
1/2010	A comparison of the potency of newly developed oximes (K347, K628) and currently available oximes (obidoxime, HI-6) to counteract acute neurotoxic effects of Tabun in rats.
3/2009	A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats.
1/2009	A comparison of neuroprotective efficacy of newly developed oximes (K203, K206) and commonly used oximes (obidoxime, HI-6) in tabun-poisoned rats.
9/2008	New bispyridinium oximes: in vitro and in vivo evaluation of their biological efficiency in soman and tabun poisoning.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kamil Kuca Research Topics

Disease

78	Poisoning 02/2022 - 01/2004
49	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 01/2004
28	Neoplasms (Cancer) 06/2022 - 11/2013
14	Organophosphate Poisoning 07/2020 - 08/2006
8	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 01/2015
7	Infections 03/2021 - 01/2010
6	COVID-19 01/2022 - 01/2021
6	Dementia (Dementias) 01/2019 - 01/2016
5	Hypoxia (Hypoxemia) 01/2022 - 01/2020
5	Body Weight (Weight, Body) 10/2021 - 01/2013
5	Myasthenia Gravis 02/2016 - 11/2009
4	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 01/2017
4	Cognitive Dysfunction 01/2019 - 01/2017
3	Inflammation (Inflammations) 01/2022 - 01/2017
3	Vomiting 01/2021 - 01/2020
3	Wounds and Injuries (Trauma) 01/2021 - 04/2019
3	Nervous System Diseases (Neurological Disorders) 04/2020 - 01/2015
3	Breast Neoplasms (Breast Cancer) 01/2020 - 12/2017
3	Pain (Aches) 06/2016 - 08/2007
3	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2016 - 01/2014
2	Amyloid Plaque 01/2022 - 01/2017
2	Cardiovascular Diseases (Cardiovascular Disease) 05/2021 - 11/2020
2	Amnesia (Dissociative Amnesia) 01/2021 - 04/2019
2	Schizophrenia (Dementia Praecox) 01/2021 - 01/2015
2	Mental Disorders (Mental Disorder) 01/2021 - 01/2019
2	Heart Failure 10/2020 - 09/2008
2	Epilepsy (Aura) 08/2020 - 01/2015
2	Parkinson Disease (Parkinson's Disease) 03/2020 - 01/2016

Drug/Important Bio-Agent (IBA)

50	OximesIBA 07/2020 - 01/2004
30	AcetylcholinesteraseIBA 01/2021 - 11/2005
30	tabunIBA 01/2019 - 12/2005
19	Nerve AgentsIBA 01/2019 - 11/2005
19	asoxime chloride (H16)IBA 01/2018 - 01/2004
17	Obidoxime Chloride (Obidoxime)IBA 09/2018 - 01/2004
16	Atropine FDA LinkGeneric 07/2020 - 01/2004
13	Tacrine (Cognex)FDA Link 01/2021 - 05/2008
13	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2020 - 03/2010
12	Pharmaceutical PreparationsIBA 01/2022 - 12/2005
12	EnzymesIBA 01/2021 - 01/2004
9	Trimedoxime (Trimedoxime Bromide)IBA 01/2013 - 01/2004
9	cyclohexyl methylphosphonofluoridate (cyclosarin)IBA 06/2009 - 11/2005
8	MycotoxinsIBA 02/2022 - 01/2007
8	Cholinergic Agents (Cholinergics)IBA 01/2020 - 01/2004
8	AntidotesIBA 12/2018 - 04/2008
7	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2015
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2014
6	Biological ProductsIBA 11/2019 - 09/2008
6	OrganophosphatesIBA 01/2018 - 01/2004
6	pralidoxime (Protopam Chloride)FDA Link 12/2011 - 11/2005
5	LigandsIBA 01/2021 - 01/2016
5	T-2 Toxin (T 2 Toxin)IBA 01/2021 - 12/2017
5	Amyloid beta-PeptidesIBA 03/2020 - 08/2012
5	SomanIBA 10/2010 - 02/2006
4	AntioxidantsIBA 05/2022 - 12/2011
4	Antiviral Agents (Antivirals)IBA 10/2021 - 01/2016
4	deoxynivalenolIBA 01/2021 - 01/2020
4	benzothiazoleIBA 01/2021 - 01/2015
4	Therapeutic UsesIBA 01/2019 - 05/2007
4	Cholinesterases (Cholinesterase)IBA 01/2017 - 08/2007
4	Phosphotransferases (Kinase)IBA 01/2016 - 01/2014
4	Cholinergic Antagonists (Anticholinergics)IBA 10/2008 - 11/2005
3	JNK Mitogen-Activated Protein KinasesIBA 01/2022 - 11/2019
3	CytokinesIBA 01/2022 - 08/2018
3	VaccinesIBA 01/2022 - 01/2017
3	Biomarkers (Surrogate Marker)IBA 11/2021 - 01/2019
3	GoldIBA 01/2021 - 10/2016
3	TrichothecenesIBA 01/2021 - 12/2017
3	Oxidoreductases (Dehydrogenase)IBA 03/2020 - 01/2017
3	trichotheceneIBA 01/2020 - 12/2017
3	diacetoxyscirpenolIBA 01/2020 - 12/2017
3	SaltsIBA 12/2019 - 01/2013
3	Memantine (Namenda)FDA Link 01/2019 - 06/2014
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2019 - 01/2015
3	Diazepam (Valium)FDA LinkGeneric 09/2018 - 01/2011
3	SarinIBA 01/2018 - 07/2005
3	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 01/2014
3	Malathion (Karbofos)FDA LinkGeneric 12/2011 - 01/2008
3	CarbamatesIBA 01/2011 - 01/2004
3	Paraoxon (E600)IBA 09/2010 - 11/2007
3	Acetylcholine (Acetylcholine Chloride)FDA Link 03/2010 - 11/2005
2	Antihypertensive Agents (Antihypertensives)IBA 05/2022 - 04/2020
2	MicroRNAs (MicroRNA)IBA 11/2021 - 01/2019
2	Free RadicalsIBA 05/2021 - 11/2020
2	quinolineIBA 01/2021 - 08/2019
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 01/2019
2	Serotonin (5 Hydroxytryptamine)IBA 01/2021 - 01/2020
2	Granisetron (Kytril)FDA LinkGeneric 01/2021 - 01/2020
2	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 01/2021 - 01/2020
2	Antipsychotic Agents (Antipsychotics)IBA 01/2021 - 01/2019
2	OxidesIBA 01/2021 - 01/2021
2	CopperIBA 01/2021 - 01/2016
2	neuropeptide Y2 receptorIBA 01/2021 - 01/2020
2	Scopolamine (Hyoscine)FDA Link 01/2021 - 04/2019
2	Antidepressive Agents (Antidepressants)IBA 04/2020 - 01/2019
2	Anticonvulsants (Antiepileptic Drugs)IBA 04/2020 - 01/2011
2	InsecticidesIBA 01/2020 - 06/2009
2	Alcohol Dehydrogenase (Alcohol Dehydrogenase (NAD+))IBA 07/2019 - 01/2017

Therapy/Procedure

31	Therapeutics 03/2021 - 02/2006
3	Drug Therapy (Chemotherapy) 11/2021 - 01/2019
2	Immunotherapy 01/2022 - 01/2021